Exact Mass: 469.14044040000005
Exact Mass Matches: 469.14044040000005
Found 270 metabolites which its exact mass value is equals to given mass value 469.14044040000005,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Indol-3-ylacetyl-myo-inositol L-arabinoside
C21H27NO11 (469.15840320000007)
RO4929097
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
O-Methyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate
C21H27NO9S (469.1406452000001)
O-Methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate is a fully acetylated thiocarbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The trans and cis rotamers differ in the orientation of the NH group with respect to sulfur.
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
Bucladesine
Dacomitinib
Ethanol and folate
Oxaprozin glucuronide
RO4929097
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators
5-O-beta-D-Glucopyranosyldihydroascorbigen
C21H27NO11 (469.15840320000007)
2-[1-[4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]indol-3-yl]acetic acid
C21H27NO11 (469.15840320000007)
O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (E)|O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (Z)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (E)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (Z)
C21H27NO9S (469.1406452000001)
N12-5(S)-N13-1(R)-L-rhamnosylarcyriaflavin
C26H19N3O6 (469.12737940000005)
5-O-beta-D-glucopyranosyl-dihydroABG|5-O-beta-D-glucopyranosyl-dihydroascorbigen
C21H27NO11 (469.15840320000007)
narciclasine-4-O-beta-D-glucopyranoside
C20H23NO12 (469.12201980000003)
Bucladesine
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CE - Phosphodiesterase inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
SRT 1720
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
CAY10589
C25H28ClN3O2S (469.15906580000006)
(indol-3-yl)acetyl-myo-inositol L-arabinoside
C21H27NO11 (469.15840320000007)
C24H27N3O7_Prolinamide, N-(4-hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)
C24H27N3O7 (469.18489120000004)
3-hydroxy-2-[[1-[2-[(4-hydroxybenzoyl)amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]benzoic acid
C24H27N3O7 (469.18489120000004)
Ala Cys Asn Tyr
Ala Cys Tyr Asn
Ala Asn Cys Tyr
Ala Asn Tyr Cys
Ala Tyr Cys Asn
Ala Tyr Asn Cys
Cys Ala Asn Tyr
Cys Ala Tyr Asn
Cys Cys Met Asn
Cys Cys Asn Met
Cys Phe Asn Ser
Cys Phe Ser Asn
Cys Gly Gln Tyr
Cys Gly Tyr Gln
Cys His Asn Pro
Cys His Pro Asn
Cys Met Cys Asn
Cys Met Asn Cys
Cys Asn Ala Tyr
Cys Asn Cys Met
Cys Asn Phe Ser
Cys Asn His Pro
Cys Asn Met Cys
Cys Asn Pro His
Cys Asn Ser Phe
Cys Asn Tyr Ala
Cys Pro His Asn
Cys Pro Asn His
Cys Gln Gly Tyr
Cys Gln Tyr Gly
Cys Ser Phe Asn
Cys Ser Asn Phe
Cys Tyr Ala Asn
Cys Tyr Gly Gln
Cys Tyr Asn Ala
Cys Tyr Gln Gly
Phe Cys Asn Ser
Phe Cys Ser Asn
Phe Asn Cys Ser
Phe Asn Ser Cys
Phe Ser Cys Asn
Phe Ser Asn Cys
Gly Cys Gln Tyr
Gly Cys Tyr Gln
Gly Gln Cys Tyr
Gly Gln Tyr Cys
N1-Demethylnicergoline
Gly Tyr Cys Gln
Gly Tyr Gln Cys
His Cys Asn Pro
His Cys Pro Asn
His Asn Cys Pro
His Asn Pro Cys
His Pro Cys Asn
His Pro Asn Cys
Met Cys Cys Asn
Met Cys Asn Cys
Met Asn Cys Cys
Asn Ala Cys Tyr
Asn Ala Tyr Cys
Asn Cys Ala Tyr
Asn Cys Cys Met
Asn Cys Phe Ser
Asn Cys His Pro
Asn Cys Met Cys
Asn Cys Pro His
Asn Cys Ser Phe
Asn Cys Tyr Ala
Asn Phe Cys Ser
Asn Phe Ser Cys
Asn His Cys Pro
Asn His Pro Cys
Asn Met Cys Cys
Asn Pro Cys His
Asn Pro His Cys
Asn Ser Cys Phe
Asn Ser Phe Cys
Asn Ser Ser Tyr
C19H27N5O9 (469.18086919999996)
Asn Ser Tyr Ser
C19H27N5O9 (469.18086919999996)
Asn Tyr Ala Cys
Asn Tyr Cys Ala
Asn Tyr Ser Ser
C19H27N5O9 (469.18086919999996)
Pro Cys His Asn
Pro Cys Asn His
Pro His Cys Asn
Pro His Asn Cys
Pro Asn Cys His
Pro Asn His Cys
Gln Cys Gly Tyr
Gln Cys Tyr Gly
Gln Gly Cys Tyr
Gln Gly Tyr Cys
Gln Tyr Cys Gly
Gln Tyr Gly Cys
Ser Cys Phe Asn
Ser Cys Asn Phe
Ser Phe Cys Asn
Ser Phe Asn Cys
Ser Asn Cys Phe
Ser Asn Phe Cys
Ser Asn Ser Tyr
C19H27N5O9 (469.18086919999996)
Ser Asn Tyr Ser
C19H27N5O9 (469.18086919999996)
Ser Ser Asn Tyr
C19H27N5O9 (469.18086919999996)
Ser Ser Tyr Asn
C19H27N5O9 (469.18086919999996)
Ser Tyr Asn Ser
C19H27N5O9 (469.18086919999996)
Ser Tyr Ser Asn
C19H27N5O9 (469.18086919999996)
Tyr Ala Cys Asn
Tyr Ala Asn Cys
Tyr Cys Ala Asn
Tyr Cys Gly Gln
Tyr Cys Asn Ala
Tyr Cys Gln Gly
Tyr Gly Cys Gln
Tyr Gly Gln Cys
Tyr Asn Ala Cys
Tyr Asn Cys Ala
Tyr Asn Ser Ser
C19H27N5O9 (469.18086919999996)
Tyr Gln Cys Gly
Tyr Gln Gly Cys
Tyr Ser Asn Ser
C19H27N5O9 (469.18086919999996)
Tyr Ser Ser Asn
C19H27N5O9 (469.18086919999996)
NVP-BEZ235
N-(4-Hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)prolinamide
C24H27N3O7 (469.18489120000004)
Belotecan hydrochloride
C25H28ClN3O4 (469.1768238000001)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D004791 - Enzyme Inhibitors
1-[2-[[4-[(2-chloro-4-nitrophenyl)azo]phenyl]ethylamino]ethyl]pyridinium acetate
C23H24ClN5O4 (469.15167340000005)
b-D-Galactopyranoside,4-nitrophenyl, 2,3,4,6-tetraacetate
C20H23NO12 (469.12201980000003)
Dacomitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
fmoc-(s)-3-amino-4-(2-trifluoromethyl-phenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
BENZENE, 1,1-[(4-NITROPHENYL)METHYLENE]BIS[2,4,6-TRIMETHOXY]-
C25H27NO8 (469.17365820000003)
2-Nitrophenyl2,3-di-O-acetyl-4-O-triethylsilyl-b-D-xylopyranoside
C21H31NO9Si (469.17679960000004)
Fmoc-(S)-3-Amino-4-(4-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
dimenhydrinate
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Dimenhydrinate is an orally active H1-antihistamine consisting of Diphenhydramine (HY-B0303) and 8-Chlorotheophylline. Dimenhydrinate is used to prevent nausea, vomiting, dizziness, and vertigo associated with motion sickness[1].
Fmoc-(R)-3-Amino-4-(2-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
Fmoc-(R)-3-Amino-4-(4-trifluoromethyl-phenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
Fmoc-(S)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
(6R)-3,8-dioxo-7t-(2-phenyl-acetylamino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]octane-2ξ-carboxylic acid 4-nitro-benzyl ester
C22H19N3O7S (469.09436640000007)
Almotriptan
C21H31N3O7S (469.18826160000003)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine. IC50: Target: 5-hydroxytryptamine1B/1D (5-HT1B/1D) Receptor Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less. Almotriptan did not exhibit significant affinity for several non-5-HT receptors studied up to 100 microM. Almotriptan inhibited forskolin-stimulated cyclic AMP accumulation in HeLa cells transfected with 5-HT(1B) or 5-HT(1D) human receptors [1]. Almotriptan had a mild antiemetic effect and a slight, transient diuretic effect in dogs, although the latter effect is probably of no clinical relevance. In addition, no effect on the respiratory system of conscious guinea pigs was observed following almotriptan treatment. These results indicate that almotriptan has a favourable safety profile with respect to the central nervous, renal and respiratory systems [2].
(4-METHYL-THIAZOL-2-YL)-PHENYL-AMINE
C20H23NO12 (469.12201980000003)
a-D-Galactopyranoside,4-nitrophenyl, 2,3,4,6-tetraacetate
C20H23NO12 (469.12201980000003)
benzylpenicillin β-diethylaminoethyl ester hydrochloride
C22H32ClN3O4S (469.1801942000001)
4-nitrophenyl tetra-o-acetyl-beta-d-glucopyranoside
C20H23NO12 (469.12201980000003)
Gandotinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
(2R,3S,4R,5R)-2-(hydroxyMethyl)-5-(6-((2-(Methylthio)ethyl)aMino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
C16H22F3N5O4S2 (469.10652480000005)
Fmoc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
C26H22F3NO4 (469.15008480000006)
2-(2-phenyl-9H-carbazol-9-yl)dibenzo[b,d]thiophen-4-ylboronic acid
C30H20BNO2S (469.13077300000003)
D-Glucopyranose, 2-azido-2-deoxy-3,4-bis-O-(phenylMethyl)-, 1,6-diacetate
C24H27N3O7 (469.18489120000004)
4-[(4-Chlorophenyl)-2-pyridylmethoxy]piperidine p-nitrobenzoic acid salt
C24H24ClN3O5 (469.14044040000005)
Ki8751
C24H18F3N3O4 (469.12493440000003)
(E)-N-(4-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide
C24H27N3O5S (469.1671332000001)
Mycophenolate mofetil hydrochloride
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents C471 - Enzyme Inhibitor > C2087 - Inosine Monophosphate Dehydrogenase Inhibitor C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
Sofpironium bromide
C22H32BrNO5 (469.14637220000003)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes[1].
CID 54733074
3-fluoro-N-[4-[[4-(4-methoxyphenyl)-1-piperazinyl]-oxomethyl]phenyl]benzenesulfonamide
C24H24FN3O4S (469.14714760000004)
3-(4-{2-[2-(2-Bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
(4as,4br,10bs,12as)-12a-Methyl-1,3-Dioxo-2-(Pyridin-3-Ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-Dodecahydronaphtho[2,1-F]isoquinolin-8-Yl Sulfamate
C24H27N3O5S (469.1671332000001)
(2s,4s,5r)-2-Isobutyl-5-(2-Thienyl)-1-[4-(Trifluoromethyl)benzoyl]pyrrolidine-2,4-Dicarboxylic Acid
C22H22F3NO5S (469.1170718000001)
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methyl 2-[3-methoxy-2-[(5-phenyl-1,2-oxazole-3-carbonyl)amino]phenyl]-1,3-benzoxazole-4-carboxylate
C26H19N3O6 (469.12737940000005)
2-[(4-{[([1,1-Biphenyl]-4-yl)methyl]amino}-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
C25H28ClN3O2S (469.15906580000006)
(2S)-2-[[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-formylamino]phenyl]-hydroxymethyl]amino]pentanedioic acid
6-[3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
2-(4-Nitrophenoxy)-1-[4-(4-phenylphthalazin-1-yl)piperazin-1-yl]ethanone
C26H23N5O4 (469.17499580000003)
(indol-3-ylacetyl)-myo-inositol 3-L-arabinoside
C21H27NO11 (469.15840320000007)
[5-(4-Fluorophenyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[2-(3-pyridinyl)-1-piperidinyl]methanone
3-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester
C25H27NO6S (469.1559002000001)
(4-oxo-2,3-dihydro-1H-cyclopenta[c]chromen-7-yl) 4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoate
C25H27NO6S (469.1559002000001)
[2-(2-Methylpropylcarbamoylamino)-2-oxoethyl] 3-[(3,4-difluorophenyl)sulfonylamino]benzoate
C20H21F2N3O6S (469.11190700000003)
3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}benzimidazo[1,2-c]quinazoline-6(5H)-thione
7-(4-chlorophenyl)-4-(2-fluorophenyl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid 2-methoxyethyl ester
C26H25ClFNO4 (469.14560520000003)
1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl}-1,3-diazinane-2,4-dione
C19H27N5O9 (469.18086919999996)
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
10-(2-Amino-ethylamino)-9-(3-chloro-phenyl)-2,2,5-trimethyl-1,4-dihydro-2H,9H-3-oxa-7-thia-6,9,11-tria za-benzo[c]fluoren-8-one
C23H24ClN5O2S (469.13391540000003)
N-(2-fluorophenyl)-2-[[7-(2-fluorophenyl)-1,3-dimethyl-2,4-dioxo-5-pyrimido[4,5-d]pyrimidinyl]thio]acetamide
C22H17F2N5O3S (469.1020116000001)
6-amino-1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-hydroxy-5-methyl-3,4-dihydro[4,4-bipyrimidine]-2,2(1H,3H)-dione
C19H27N5O9 (469.18086919999996)
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
dihydroascorbigen 5-O-beta-D-glucoside
C21H27NO11 (469.15840320000007)
A dihydroascorbigen hexoside in which the hexoside component is a beta-D-glucosyl residue attached at position 5 via a glycosidic bond.
butanoic acid [(4aS,5R,6R,7aR)-2-hydroxy-2-oxo-6-[6-(1-oxobutylamino)-9-purinyl]-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3,2]dioxaphosphorin-5-yl] ester
2-[(2R,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(2R,3R,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2S,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(2S,3R,6S)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
1-[(2R,3S,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2R,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-(3-chlorophenyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(2S,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2S,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2R,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(1S)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
C25H28ClN3O4 (469.1768238000001)
1-(3-chlorophenyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(2R,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
2-[(2S,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
C21H31N3O7S (469.18826160000003)
1-[(1R)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
C25H28ClN3O4 (469.1768238000001)
1-[(1S)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
C25H28ClN3O4 (469.1768238000001)
1-[(1R)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C24H27N3O5S (469.1671332000001)
2-methoxyethyl (4S,7S)-7-(4-chlorophenyl)-4-(2-fluorophenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
C26H25ClFNO4 (469.14560520000003)
6-amino-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}hexanamide
methyl (2S)-2-[[(2Z)-2-(3,5-dioxo-4-phenyloxolan-2-ylidene)-2-phenylacetyl]amino]-3-phenylpropanoate
[(4aR,5R,6R,7aR)-6-[6-(butanoylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3,2]dioxaphosphinin-5-yl] butanoate
butanoic acid [(4aS,6S,7S,7aS)-2-hydroxy-2-oxo-6-[6-(1-oxobutylamino)-9-purinyl]-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-yl] ester
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[2-(hydroxymethyl)-3-oxo-1-phenylpropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(3-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-3-oxo-1-phenylbutyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
(2S)-2-azaniumyl-5-{[(2R)-1-[(carboxylatomethyl)amino]-1-oxo-3-{[(2-phenylethyl)carbamothioyl]sulfanyl}propan-2-yl]amino}-5-oxopentanoate
oxolan-2-ylmethyl 4-(6-chloro-4-oxochromen-3-yl)-2-methyl-5-oxo-4a,6,7,8-tetrahydro-4H-quinoline-3-carboxylate
C25H24ClNO6 (469.12920740000004)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-2-methyl-3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-2-methyl-3-oxo-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-3-oxo-1-phenylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-methoxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C20H27N3O8S (469.15187820000006)
[(2S,3S,5R,6R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-cyclohexyl] 2-(1H-indol-3-yl)acetate
C21H27NO11 (469.15840320000007)
(4-Methoxybenzyl)thiocarbamic acid 4-O-(tri-O-acetyl-alpha-L-rhamnopyranoside)
C21H27NO9S (469.1406452000001)
2-deoxycytidine-thymidine dimer
C19H27N5O9 (469.18086919999996)
A nucleoside analogue obtained by formal cyclodimerisation of 2-deoxycytidine and thymidine.
Inauhzin
Inauhzin is a dual SirT1/IMPDH2 inhibitor, and acts as an activator p53, used in the research of cancer.
(2s,3r,4s)-4-{[(2r,3s,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,4ah,9h-[1,3]dioxolo[4,5-j]phenanthridine-2,3,6,7-tetrol
C20H23NO12 (469.12201980000003)
(3s,4r,5s)-3,4-dihydroxy-5-[(1s)-2-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-3-(1h-indol-3-ylmethyl)oxolan-2-one
C21H27NO11 (469.15840320000007)
10-Formylfolic acid
-